View ValuationHelyx Industries 향후 성장Future 기준 점검 2/6Helyx Industries (는) 각각 연간 45.4% 및 35.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 33.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 4.7% 로 예상됩니다.핵심 정보45.4%이익 성장률33.14%EPS 성장률Biotechs 이익 성장22.8%매출 성장률35.7%향후 자기자본이익률4.70%애널리스트 커버리지Low마지막 업데이트03 Jun 2026최근 향후 성장 업데이트Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.모든 업데이트 보기Recent updatesNew Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.9m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Revenue is less than US$5m (€1.9m revenue, or US$2.2m). Market cap is less than US$100m (€15.8m market cap, or US$18.3m).Reported Earnings • Apr 16Full year 2025 earnings releasedFull year 2025 results: Revenue: €2.23m (up 191% from FY 2024). Net loss: €4.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Europe.New Risk • Apr 15New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 61% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.3m net loss in 2 years). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€15.3m market cap, or US$18.0m).공시 • Apr 14Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: via montebello n 27, milano ItalyNew Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.7m). Currently unprofitable and not forecast to become profitable over next 3 years (€3.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.2% average weekly change). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€16.4m market cap, or US$18.9m).Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.Reported Earnings • Oct 10First half 2025 earnings released: €0.099 loss per share (vs €0.14 loss in 1H 2024)First half 2025 results: €0.099 loss per share (improved from €0.14 loss in 1H 2024). Net loss: €2.43m (loss narrowed 21% from 1H 2024). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Buy Or Sell Opportunity • Sep 30Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 79% to €1.35. The fair value is estimated to be €1.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Sep 15Now 20% undervaluedOver the last 90 days, the stock has risen 11% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Aug 22Now 21% undervaluedOver the last 90 days, the stock has risen 6.8% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Aug 06Now 21% undervaluedOver the last 90 days, the stock has risen 20% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Jun 16Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.78. The fair value is estimated to be €1.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • May 16Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.8% to €0.75. The fair value is estimated to be €1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (€768k revenue, or US$852k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.6m). Currently unprofitable and not forecast to become profitable over next 3 years (€2.3m net loss in 3 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€20.5m market cap, or US$22.8m).공시 • Apr 15Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025, at 15:00 W. Europe Standard Time.Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.Reported Earnings • May 21Full year 2023 earnings releasedFull year 2023 results: Net loss: €4.80m (loss widened 267% from FY 2022). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€27.8m market cap, or US$30.2m).Buy Or Sell Opportunity • May 11Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 25% to €1.17. The fair value is estimated to be €1.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.Buy Or Sell Opportunity • Apr 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to €1.23. The fair value is estimated to be €1.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$97k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€29.8m market cap, or US$31.6m).New Risk • Jan 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 167% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risk Market cap is less than US$100m (€40.6m market cap, or US$44.4m).Buying Opportunity • Sep 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.5%. The fair value is estimated to be €2.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.1% over the last 3 years. Earnings per share has declined by 16%. Revenue is forecast to grow by 575% in a year. Earnings is forecast to grow by 79% in the next year.분석 기사 • Jun 24A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)Key Insights Ulisse Biomed's estimated fair value is €1.52 based on 2 Stage Free Cash Flow to Equity Ulisse Biomed's...분석 기사 • Feb 17We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.Buying Opportunity • May 31Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €2.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 289% in 2 years. Earnings is forecast to grow by 85% in the next 2 years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.85, the stock trades at a trailing P/E ratio of 74.2x. Average forward P/E is 38x in the Biotechs industry in Europe.이익 및 매출 성장 예측BIT:HLX - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20288-211212/31/20275-200212/31/20263-300212/31/20252-4-2-2N/A9/30/20251-5N/AN/AN/A6/30/20251-5-3-3N/A3/31/20251-6-3-3N/A12/31/20241-6-4-4N/A9/30/20241-6N/AN/AN/A6/30/20240-7-2-2N/A3/31/20240-6-2-1N/A12/31/20230-5-1-1N/A9/30/20230-3N/AN/AN/A6/30/20230-2-2-1N/A3/31/20230-1-1-1N/A12/31/20220-1-1-1N/A9/30/20220-1N/AN/AN/A6/30/20220-1-2-1N/A3/31/20220-1-2-1N/A12/31/20210-1-10N/A9/30/202100N/AN/AN/A6/30/20211001N/A3/31/20211000N/A12/31/202010-1-1N/A12/31/20190-100N/A12/31/20180-2N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: HLX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: HLX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: HLX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: HLX 의 수익(연간 35.7%)이 Italian 시장(연간 5.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: HLX 의 수익(연간 35.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: HLX의 자본 수익률은 3년 후 4.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/14 03:36종가2026/06/12 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Helyx Industries S.p.A.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mattia PetraccaIntegrae SPAGuglielmo Marco OpipariIntermonte SIM S.p.A.Valentina RomitelliValueTrack
Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.
Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.
Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.
New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.9m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Revenue is less than US$5m (€1.9m revenue, or US$2.2m). Market cap is less than US$100m (€15.8m market cap, or US$18.3m).
Reported Earnings • Apr 16Full year 2025 earnings releasedFull year 2025 results: Revenue: €2.23m (up 191% from FY 2024). Net loss: €4.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
New Risk • Apr 15New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 61% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.3m net loss in 2 years). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€15.3m market cap, or US$18.0m).
공시 • Apr 14Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: via montebello n 27, milano Italy
New Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.7m). Currently unprofitable and not forecast to become profitable over next 3 years (€3.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.2% average weekly change). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€16.4m market cap, or US$18.9m).
Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.
Reported Earnings • Oct 10First half 2025 earnings released: €0.099 loss per share (vs €0.14 loss in 1H 2024)First half 2025 results: €0.099 loss per share (improved from €0.14 loss in 1H 2024). Net loss: €2.43m (loss narrowed 21% from 1H 2024). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Sep 30Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 79% to €1.35. The fair value is estimated to be €1.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Sep 15Now 20% undervaluedOver the last 90 days, the stock has risen 11% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Aug 22Now 21% undervaluedOver the last 90 days, the stock has risen 6.8% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Aug 06Now 21% undervaluedOver the last 90 days, the stock has risen 20% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Jun 16Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.78. The fair value is estimated to be €1.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • May 16Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.8% to €0.75. The fair value is estimated to be €1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (€768k revenue, or US$852k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.6m). Currently unprofitable and not forecast to become profitable over next 3 years (€2.3m net loss in 3 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€20.5m market cap, or US$22.8m).
공시 • Apr 15Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025, at 15:00 W. Europe Standard Time.
Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.
Reported Earnings • May 21Full year 2023 earnings releasedFull year 2023 results: Net loss: €4.80m (loss widened 267% from FY 2022). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€27.8m market cap, or US$30.2m).
Buy Or Sell Opportunity • May 11Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 25% to €1.17. The fair value is estimated to be €1.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.
Buy Or Sell Opportunity • Apr 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to €1.23. The fair value is estimated to be €1.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$97k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€29.8m market cap, or US$31.6m).
New Risk • Jan 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 167% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risk Market cap is less than US$100m (€40.6m market cap, or US$44.4m).
Buying Opportunity • Sep 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.5%. The fair value is estimated to be €2.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.1% over the last 3 years. Earnings per share has declined by 16%. Revenue is forecast to grow by 575% in a year. Earnings is forecast to grow by 79% in the next year.
분석 기사 • Jun 24A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)Key Insights Ulisse Biomed's estimated fair value is €1.52 based on 2 Stage Free Cash Flow to Equity Ulisse Biomed's...
분석 기사 • Feb 17We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.
Buying Opportunity • May 31Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €2.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 289% in 2 years. Earnings is forecast to grow by 85% in the next 2 years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.85, the stock trades at a trailing P/E ratio of 74.2x. Average forward P/E is 38x in the Biotechs industry in Europe.